Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04217993
Collaborator
(none)
49
Enrollment
1
Location
4
Arms
32.4
Anticipated Duration (Months)
1.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib. The experiment is divided into two parts: dose exploration and extended research.

Condition or DiseaseIntervention/TreatmentPhase
  • Drug: Jaktinib hydrochloride tablets
Phase 2

Detailed Description

dose exploration: It is planned to enroll about 6 subjects. According to the baseline value of platelet count at the time of enrollment, different doses (100mg Qd or 150mg Qd or 200mg Qd or 100mg Bid) of Jaktinib Hydrochloride Tablets will be Treated. The trial is in progress Adjust the dose according to relevant laboratory indicators. When at least one subject has a spleen volume reduction of ≥35% from the baseline, the sponsor and the investigator will jointly decide whether to enter the extended study part.

Extended research: It is planned to enroll about 43 subjects, and the initial dosage of Jaktinib Hydrochloride Tablets is planned to be 100mg Bid.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
49 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Jaktinib Dihydrochloride Monohydrate in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib
Actual Study Start Date :
Jan 7, 2020
Anticipated Primary Completion Date :
Jul 18, 2022
Anticipated Study Completion Date :
Sep 18, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Jaktinib Hydrochloride Tablets 100mg twice a day.

This is the dose group was given Jaktinib Hydrochloride Tablets 100mg (2 tablets)dose group for twice a day.

Drug: Jaktinib hydrochloride tablets
Jaktinib hydrochloride tablets 100mg twice dose group,Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
Other Names:
  • Jaktinib
  • Experimental: Jaktinib Hydrochloride Tablets 150mg once a day

    This is the dose group was given Jaktinib Hydrochloride Tablets 150mg (3 tablets)dose group for once a day.

    Drug: Jaktinib hydrochloride tablets
    Jaktinib hydrochloride tablets 100mg twice dose group,Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
    Other Names:
  • Jaktinib
  • Experimental: Jaktinib Hydrochloride Tablets 100mg once a day

    This is the dose group was given Jaktinib Hydrochloride Tablets 100mg (2 tablets) dose group for once a day

    Drug: Jaktinib hydrochloride tablets
    Jaktinib hydrochloride tablets 100mg twice dose group,Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
    Other Names:
  • Jaktinib
  • Experimental: Jaktinib Hydrochloride Tablets 200mg once a day

    This is the dose group was given Jaktinib Hydrochloride Tablets 200mg (4 tablets)dose group for once a day.

    Drug: Jaktinib hydrochloride tablets
    Jaktinib hydrochloride tablets 100mg twice dose group,Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
    Other Names:
  • Jaktinib
  • Outcome Measures

    Primary Outcome Measures

    1. response rate [up to 24 weeks]

      The proportion of all subjects whose spleen volume decreased by 35% or more at 24 weeks

    Secondary Outcome Measures

    1. Objective response rate [up to 24 weeks]

      IWG-MRT efficacy criteria

    2. Anemia response rate [up to 24 weeks]

      Proportion of anemia response in all of anemia patients

    3. Total symptoms score(TSS) response rate [up to 24 weeks]

      TSS response is defined as the proportion of subjects who achieve a ≥ 50% reduction in TSS at the Week 24 compared to baseline

    4. Progression-free survival [up to 24 weeks]

      The time from the date of enrollment to the date on which any of the following events occurred:①Spleen volume increased by ≥25% compared to the lowest value recorded during the trial including baseline;②Death from any cause

    5. Leukemia-free survival [up to 2 years]

      The time elapsed from the date of enrollment to the date of any of the following events:①The first bone marrow smear shows the date of ≥20% of the original cells;②The first peripheral blood smear showed ≥20% of the original cells and the absolute value of the original cells was ≥1×10^9/L for at least 2 weeks;③Death from any cause。

    6. Overall survival [up to 2 years]

      Time elapsed from the date of enrollment to death from any cause

    7. Adverse event rate [up to 28 weeks]

      Vital signs, physical examination, blood routine; severity and incidence of adverse events and adverse reactions (NCI-CTCAE V4.03)

    8. Thrombotic event rate [up to 28 weeks]

      Arterial thrombosis:①Coronary heart disease;②Cerebral arterial thrombosis;③Peripheral arterial occlusive disease:Such as mesenteric artery thrombosis and extremity arterial thrombosis。Venous thrombosis:①Thrombophlebitis;②Deep vein thrombosis;③Pulmonary embolism。Microcirculatory thrombosis: ① thrombotic thrombocytopenic purpura; ② hemolytic uremic syndrome; ③ extracorporeal circulation thrombosis; ④other: such as fulminant purple epilepsy and disseminated intravascular coagulation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age greater than or equal to 18 years old ,male or female;

    2. Patients diagnosed with Primary Myelofibrosis according to WHO standard (2016 version), or patients diagnosed with Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis according to International Working Group Myeloproliferative Neoplasms Research and Treatment(IWG-MRT) standard. Both Janus Kinase 2(JAK2)mutation and JAK2 wild can be enrolled;

    3. According to Dynamic International Prognostic Scoring System plus(DIPSS-plus) risk grouping criteria, patients with medium-risk-2 or high-risk myelofibrosis were assessed,Patients with grade 1 medium-risk myelofibrosis with hepatosplenomegaly and no response to existing treatment and requiring treatment can also be enrolled;

    4. Patients who have received or are receiving Ruxolitinib,and:Ruxolitinib treatment time is not less than 28 days;Red blood cell transfusion is still needed during treatment with Ruxolitinib;or Ruxolitinib dose (including starting dose and adjusted dose)<20mg bid,And must meet at least one of the following:Level 3 or higher platelet count reduction or Level 3 or higher anemia or Level 3 or higher hematoma/bleeding;

    5. a life expectancy > 24 weeks;

    6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;

    7. Splenomegaly: palpation of the splenic margin to or above the subcostal at least 5cm;

    8. Within 14 days before enrollment,The Laboratory indicators meet the following criteria:

    • Absolute neutrophil count(ANC) > 0.75 x 109/L,blood platelet count> 30 x 109/L,And no colony stimulating factor was used within 7 days before screening;

    • Peripheral blood blast < 10%;

    • AST和ALT≤3xULN,Patients with severe extramedullary hematopoiesis or who have received iron therapy within 60 days prior to screening and thus have liver function damage,AST和ALT≤5xULN ;

    • Direct bilirubin≤2.0*ULN

    • Creatinine clearance≥45mL/min;

    1. Meet the requirements of the Ethics Committee, voluntarily sign an informed consent form;

    2. Ability to follow research and follow-up procedures;

    Exclusion Criteria:
    1. Any significant clinical or laboratory abnormalities that the investigator considers to affect safety assessment, such as: a. uncontrolled diabetes (> 250 mg/dL, or 13.9>mmol/L), b. had high blood pressure and antihypertensive drug treatment under two or unable to descend to the ranges (systolic blood pressure < 160 mmHg, diastolic pressure < 100 mmHg), c. peripheral neuropathy (NCI - CTC AE v5.0 standard grade 2 or above), etc;

    2. The patients who had a history of congestive heart failure(NCI - CTC AE v5.0 standard grade 3or above), uncontrollable or unstable angina or myocardial infarction, cerebrovascular accident or pulmonary embolism in the first 6 months;

    3. Screening of patients who have surgery within the first 4 weeks;

    4. Screening for patients with arrhythmia requiring treatment or QTc interval (QTcB)

    480ms;

    1. Screening for bacterial, viral, parasitic or fungal infections that require treatment;

    2. Patients which have with a history of congenital or acquired hemorrhagic diseases;(Note:With the exception of hematoma which caused by Ruxolitinib)

    3. Splenectomy patients or in the group carried out within three months before the spleen radiation treatment (including internal radiation and external radiation)

    4. Screening HIV, HBV DNA positive or higher than the normal reference range, or HCV RNA positive for HCV antibody;

    5. Women who are planning to become pregnant or who are pregnant or breast- feeding, as well as those who were unable to use effective contraceptives throughout the trial;Male patients who do not use condoms during the administration and within 2 days (approximately 5 half-lives) after the last administration;

    6. Patients who have suffered from malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) in the past 5 years; Combined with other serious diseases, the researchers believe that patients' safety or compliance may be affected;

    7. With other serious diseases, the researchers think that may affect patient safety or compliance;

    8. The patients who had used the Jakatinib hydrochloride;

    9. Patients who have participated in the clinical trials of other new drugs or medical devices within the first 1 months;

    10. The patients who used the Hematopoietic growth factors within 14 days before Into the group (granulocyte growth factors, or platelet hormone) ;

    11. Patients who cannot cooperate with or cannot perform MRI or CT scans;

    12. Patients with refractory or recurrent myelofibrosis:

    refractory of myelofibrosis:After at least 28 days of adequate administration of JAK inhibitors, the spleen palpation was less than 15% smaller than before administration.Or at least 3 months later, the spleen volume on MRI/CT decreased by <10% compared with that before the administration.

    Recurrence of myelofibrosis: after at least 3 months of taking adequate amount of JAK inhibitor, the spleen was enlarged again after shrinking compared with that before taking the drug, and compared with the minimum value during taking the drug, the spleen volume increased ≥10% on MRI/CT examination or ≥30% on spleen palpation.

    1. Any treatment MF medication (eg hydroxyurea,except ruxolitinib ), any immunomodulation used within 2 weeks prior to enrollment Agent (such as thalidomide), any immunosuppressant, glucocorticoids ≥ 10 mg/day of prednisone or equivalent biological strength, or patients within 6 half-life of the drug, over time Prevail;Patients who had received rucotinib within 1 week prior to enrolling

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1The First Affiliated Hospital of Medical School of Zhejiang UniversityHangzhouZhejiangChina310003

    Sponsors and Collaborators

    • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Investigators

    • Study Chair: Jie Jin, MD, The First Affiliated Hospital of Medical School of Zhejiang University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    ClinicalTrials.gov Identifier:
    NCT04217993
    Other Study ID Numbers:
    • ZGJAK006
    First Posted:
    Jan 6, 2020
    Last Update Posted:
    Jun 16, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 16, 2021